about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Chi­nese gov­ern­ment probe con­demns Jiankui He as rogue sci­en­tist pur­su­ing 'il­le­gal' work on gene-edit­ed ba­bies

7 years ago
China

John Mendlein leaves Mod­er­na for Flag­ship; Paul Sekhri to steer first xeno­trans­plan­ta­tion tri­als as eGe­n­e­sis CEO

7 years ago
Peer Review

Cel­gene inks first deals since Bris­tol-My­ers an­nounced $74B buy­out — bets $80M on im­munome­tab­o­lism

7 years ago
Pharma

No­var­tis teams up with Ox­ford re­searchers to crunch big da­ta in­to clin­i­cal in­sights

7 years ago
AI

NIH re­searchers re­port an­i­mal mod­el val­i­da­tion for stem cell-based ap­proach to ad­vanced dry AMD

7 years ago
Discovery

Alzheon hits an­oth­er dead end fund­ing its Alzheimer's pro­gram, pulls sec­ond IPO at­tempt

7 years ago
Financing
R&D

Drag­on­fly preps clin­i­cal take­off, ink­ing a col­lab­o­ra­tion pact with MD An­der­son

7 years ago
R&D
Pharma

Block­ing PD-L1 pro­duc­tion in mice, UCSF team spot­lights pre­clin­i­cal promise of a Pfiz­er-backed I/O drug

7 years ago
Discovery

In a first, Chi­na’s BeiGene scores FDA ‘break­through’ sta­tus for BTK in­hibitor — po­ten­tial ri­val for ...

7 years ago
China
Pharma

Mer­ck high­lights cru­cial hit for Keytru­da in sec­ond-line esophageal car­ci­no­ma — but there are al­so 2 miss­es

7 years ago
R&D

Is JPM worth it? As the buzzy con­fer­ence dies down, de­bate on its val­ue rum­bles on

7 years ago
Pharma

Kalei­do, Cir­ius brace the IPO mar­ket seek­ing a com­bined $186M — de­spite bar­ri­ers at shut­down-mode SEC

7 years ago
Financing

Iron­wood re­cruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant

7 years ago
Peer Review

An­ti-ag­ing start­up Ele­vian en­lists In­sil­i­co on AI quest for 'y­oung blood'

7 years ago
AI
Discovery

CAN­bridge ex­pands rare dis­ease pact with WuXi Bi­o­log­ics; Watch for a man­u­fac­tur­ing site from Al­lo­gene

7 years ago
News Briefing

As­traZeneca chops 210 work­ers, clos­es sites as it looks to con­cen­trate bi­o­log­ics man­u­fac­tur­ing in one place

7 years ago
R&D
Outsourcing

Roche ex­ec Pearl Huang re­joins biotech as CEO of Cyg­nal — Flag­ship's bet on 'ex­oneur­al bi­ol­o­gy'

7 years ago
People
Peer Review

An­ti-ag­ing start­up Uni­ty dives in­to eye dis­eases as part­ner­ship with As­cen­t­age bears fruit

7 years ago
Pharma

Ramp­ing up in-house drug de­vel­op­ment, API mak­er Bright­Gene bags $80M round led by Se­quoia Chi­na

7 years ago
Financing
China

Prep­ping a cross-Pa­cif­ic move, Or­biMed-backed Apol­lomics bags $100M Se­ries B for I/O com­bos

7 years ago
Financing
China

Bill Gates backs Schrödinger's $85M ven­ture raise for its stand­out com­pu­ta­tion­al drug dis­cov­ery plat­form

7 years ago
Financing

Atara seeks new CEO as Isaac Ciechanover ex­its; As­traZeneca's Mark Mal­lon tapped to re­place Pe­ter Hecht at Iron­wood

7 years ago
Peer Review

Join­ing forces with Sky­hawk, C4 Ther­a­peu­tics, Bio­gen buys more shots on goal on SMA, Alzheimer's

7 years ago
Pharma

Ax­ing staff and shelv­ing can­cer pro­grams, Se­lec­ta hopes laser fo­cus on gout will prove a way out

7 years ago
R&D
First page Previous page 105106107108109110111 Next page Last page
A service from the Financial Times